Rifampicin

SKU
R-2639
  • CAS:13292-46-1
  • Formula:C43H58N4O12
  • MW:823.0 Da
  • Appearance:Faint orange to red-brown powder.
  • Purity:>95%

1

0

0

Product Name Qty
RIFAMPICIN
25 g
$608.80
RIFAMPICIN
1 g
$57.02
RIFAMPICIN
5 g
$203.98

Interferes with synthesis of nucleic acids by inhibiting DNA dependent RNA polymerase. Active against gram positive bacteria. Less active against gram negative bacteria. Plant cell culture tested.

More Information
Alternate Name/Synonyms
Rifampin; Rifadin; Rifaldazine; Tubocin
SKU
R-2639
CAS #
13292-46-1
Chemical Name
[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-o
Chemical Formula
C43H58N4O12
Molecular Weight
823.0 Da
Appearance
Faint orange to red-brown powder.
Purity
>95%
Solubility
Dimethylformamide and alcohol
Storage Temp
-20°C
THERAPEUTIC AREA
Hepatic Disorders
USE
Rifampicin is an antibiotic that potently inhibits RNA polymerase and blocks RNA synthesis in Escherichia coli. The compound has been shown to inhibit α-synuclein fibrillation and disaggregate fibrils in a concentration-dependent manner. Data indicates that Rifampicin can activate the nuclear pregnane X receptor (PXR), which affects cytochrome P450, and the activity of glucuronosyltransferases and P-glycoprotein. Rifampicin has been shown to enhance CYP2C-mediated metabolism, affect compounds that are transported by P-glycoprotein and metabolized by CYP3A4, and has been used in tuberculosis studies. It is also widely used as an antipruritic agent in the autoimmune cholestatic liver disease, primary biliary cirrhosis (PBC). It has been shown to cause hepatitis.
Handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.Further processing of solid materials may result in the formation of combustible dusts. The potential for combustible dust formation should be taken into consideration before additional processing occurs. Provide appropriate exhaust ventilation at places where dust is formed.
Certificate of Analysis 1
Certificate of Analysis 2
Certificate of Analysis 3
GHS PICTOGRAMS
Handling Avoid contact with skin and eyes. Avoid formation of dust and aerosols.Further processing of solid materials may result in the formation of combustible dusts. The potential for combustible dust formation should be taken into consideration before additional processing occurs. Provide appropriate exhaust ventilation at places where dust is formed.
To Top